The company was incorporated in 1982 and was originally known Remee Holding Sdn Bhd (“Remee”). In 1989, after securing a successful bid for the privatization of the Veterinary Research Institute of Malaysia (VRI) vaccines production unit, it also bid to commercialize the University Putra Malaysia (UPM)’s Newcastle Disease vaccine. It won bids on condition tha Remee build its own vaccine plant within 18 months of securing the bids.
The Establishment of MVP
By 1992, alongside two other shareholders, Malaysian Technology Development Corporation (MTDC), a venture capital arm of Khazanah Holdings Berhad and Arthur Webster Pty Ltd, Australia, the establishment of Malaysian Vaccines & Pharmaceuticals Sdn Bhd was realized.
- 1994 – 1995
It started its activities by selling vaccines produced by the VRI before commencing its own production of six veterinary vaccines in 1994. These vaccines were developed by VRI, UPM and Arthur Webster.
In 1995, MTDC took over the management of MVP and diversified its marketing and production activities. Meanwhile, Arthur Webster went through several take overs, first by American Home Products Inc., and then by Fort Dodge Animal Health Inc., a company under the Wyeth Group stable.
- In 2004-2007
In 2004, MTDC bought over the remaining shares of MVP from its other shareholder and became the new majority shareholder at 77%. Under the stewardship of MTDC, MVP from its initial limited product range during its formation has progressed to a company offering sixteen vaccine formulations covering a multitude of diseases for both the poultry and swine market.
As MVP matured from a small incubator company, MTDC embarked on an initiative to scale down its investment. In 2007 it handed over the management of MVP to Hightronics Sdn Bhd to take it to new heights.
- 15 Years Collaboration
Now MVP has a solid backing in terms of an experienced team in business and finance at its helm through Hightronics Sdn Bhd, a very experienced technical team in the animal healthcare and vaccine manufacturing through both its employees and Fort Dodge as technology provider and a substantial government interest in the company through MTDC.
The above synergies are further enhanced by the close collaboration of over 15 years with VRI and UPM, both of which are the Malaysian leaders in veterinary researches.
In December 2010, a further change came when Forth Dodge was acquired by Pfizer Ltd, USA. As a result, Hightronics Sdn Bhd bought out Fort Dodge's 23%, becoming the majority shareholder. Today, Hightronic has a combined 78% of shares in MVP.
MVP – Today
To date, besides domestic sales in Malaysia, MVP’s products are sold throughout Asia and Africa covering a wide range of countries such as Indonesia, Philippines, Thailand, Vietnam, Cambodia, Myanmar, Timor Leste and Hong Kong. MVP also supplied its vaccines to the following countries through FAO and UNDP such as Bangladesh, Ghana, Angola, Nigeria, Kenya, Sudan, Ivory Coast, Zimbabwe, Zambia and Mauritius.
We have also expanded our market share into Middle East such as Egypt and South Asia as in Pakistan and Nepal.
MVP also successfully secured an approval from Japan’s Ministry of Agriculture, Food and Feed to export its vaccines into Japan. Several senior technical employees of MVP were sent to train in Japan to facilitate this endeavour.